AUPH - Aurinia Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

865.2M

Cash

350.4M

Avg Qtr Burn

-9.852M

Short % of Float

12.11%

Insider Ownership

7.03%

Institutional Own.

38.06%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lupkynis (Voclosporin) Details Lupus nephritis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Ophthalmic Solution Details Dry eye syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Details Focal segmental glomerulosclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.